Table 1 Current clinical trials targeting the BTLA/HVEM axis
Clinical trial | Disease | Therapy | Phase | Status |
|---|---|---|---|---|
NCT04773951 | Melanoma, renal carcinoma and urothelial carcinoma | Monotherapy and tifcemalimab/icatolimab +  toripalimab (anti-PD-1) | Phase I | Recruiting |
NCT05000684 | Advanced lung cancer | Monotherapy and tifcemalimab/icatolimab +  toripalimab (anti-PD-1) | Phase I | Recruiting |
NCT05427396 | Liver cancer, esophageal squamous cell carcinoma, gastric adenocarcinoma, cervical cancer, colorectal cancer | Tifcemalimab/icatolimab +  toripalimab (anti-PD-1) | Phase I | Recruiting |
NCT04929080 | Head and neck cancer and nasopharyngeal carcinoma | Monotherapy and tifcemalimab/icatolimab +  JS001 (anti-PD-1) | Phase I/II | Recruiting |
NCT04477772 | Recurrent/Refractory malignant lymphoma | Monotherapy and tifcemalimab/icatolimab +  JS001 (anti-PD-1) | Phase I | Recruiting |
NCT04137900 | Advanced unresectable solid tumor and metastatic solid tumor | Tifcemalimab/icatolimab +  toripalimab (anti-PD-1) | Phase I | Recruiting |
NCT05664971 | Advanced lung cancer | Tifcemalimab/icatolimab +  JS001 (anti-PD-1) alone or in combination with chemotherapy | Phase I/II | Recruiting |
NCT05891080 | Stage III resectable or potentially resectable non-small cell lung cancer | Tifcemalimab/icatolimab +  toripalimab (anti-PD-1) + chemotherapy + surgery | Phase II | Not recruiting yet |
NCT05789069 | Advanced renal cell carcinoma, melanoma, non-small cell lung cancer, gastric cancer, and colorectal cancer | HFB200603 (anti-BTLA) alone or in combination with tislelizumab (anti-PD-1) | Phase 1a/1b | Recruiting |